The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition-Reference-Cited by-同舟云学术

The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition

Published:2014-07-01 Issue:20 Volume:120 Page:3142-3153
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Chan Matthew M. K.¹²³,Haydu Lauren E.¹³,Menzies Alexander M.¹³,Azer Mary W. F.²,Klein Oliver²,Lyle Megan¹³,Clements Arthur²³,Guminski Alexander¹³⁴,Kefford Richard F.¹²³⁵,Long Georgina V.¹³⁵

Affiliation:

1. Melanoma Institute Australia; Sydney New South Wales Australia

2. Department of Medical Oncology; Crown Princess Mary Cancer Center, Westmead Hospital; Sydney New South Wales Australia

3. University of Sydney; Sydney New South Wales Australia

4. Department of Medical Oncology; Royal North Shore Hospital; Sydney New South Wales Australia

5. Westmead Millennium Institute, Westmead Institute for Cancer Research; Sydney New South Wales Australia

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28851/fullpdf

Reference34 articles.

1. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma;Long;J Clin Oncol,2010

2. NRAS mutation status is an independent prognostic factor in metastatic melanoma;Jakob;Cancer,2012

3. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

4. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study;McArthur;Lancet Oncol,2014

5. Dabrafenib in BRAF-mutated metastatic melanoma: a multi-centre, open-label, phase 3 randomised trial;Hauschild;Lancet,2012

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF^V600E-Mutated Anaplastic Thyroid Carcinoma;Thyroid®;2024-03-01

2. Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma;Biomedicines;2023-01-29

3. Onkologische Systemtherapie bis zum bitteren Ende?;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2022-12-05

4. Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib;Scientific Reports;2022-04-05

5. Targeted therapy for advanced cutaneous melanoma;Oncology in Clinical Practice;2022-02-22